|Bid||1.5900 x 900|
|Ask||1.6000 x 1000|
|Day's Range||1.5200 - 1.6400|
|52 Week Range||1.0400 - 4.6300|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By John Vandermosten, CFA NASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) held its first investor day following the read out of the ORCA-1 trial on September 20, 2019. The event was introduced by CFO John Bencich and included a roundtable discussion moderated by analysts Michael Higgins of Ladenburg Thalmann and Jason McCarthy of Maxim Group. The key opinion
Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the...
Achieve Life Sciences, Inc. (ACHV) released its second quarter results for 2019 and filed the companion 10-Q on August 8, 2019. No revenues were reported for the development stage company and operational expenses totaled $3.7 million producing a net loss of ($0.50) per share. During the three month period, the company completed the ORCA-1 Phase IIb study, was granted a patent for a new formulation of cytisinicline and reported statistically significant improvement in quit rates for cytisinicline.
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...
Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV ) traded sharply higher Friday morning before paring those gains. Achieve, which develops Cytisinicline – a plant-based ...
Achieve Life Sciences, Inc. (ACHV) reported topline results from its Phase IIb Ongoing Research of Cytisinicline for Addiction (ORCA)-1 trial which was launched in October 2018. The study enrolled 254 subjects, employing six arms: four with active drug and two with placebo. The primary endpoint for the ORCA-1 study was the self-reported reduction in daily smoking.
Achieve Life Sciences, Inc. (ACHV) released its first quarter results for 2019 and filed the companion 10-Q on May 15, 2019. Since our previous update two months ago, the company announced the end of the ORCA-1 trial which is expected to produce topline results mid-year.
Achieve Life Sciences, Inc. (ACHV) announced that its final enrollee had completed their final visit in the Phase IIb ORCA-1 trial on Wednesday. As a reminder the ORCA-1 (Ongoing Research of Cytisinicline for Addiction) trial is evaluating the effectiveness of cytisinicline for smoking cessation. The trial was designed as a multicenter, double blind, placebo-controlled trial in adult smokers randomized in a 2:2:1 ratio at 1.5 mg, 3.0 mg and placebo.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.
Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Achieve Life Sciences, Inc. (NASDAQ:ACHV)Read More...
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals